Poltreg S.A. (WSE:PTG)

Poland flag Poland · Delayed Price · Currency is PLN
24.10
-0.90 (-3.60%)
Dec 8, 2025, 9:45 AM CET
-45.60%
Market Cap116.59M
Revenue (ttm)n/a
Net Income (ttm)-24.56M
Shares Out4.66M
EPS (ttm)-5.27
PE Ration/a
Forward PE48.58
Dividendn/a
Ex-Dividend Daten/a
Volume4,274
Average Volume2,724
Open24.80
Previous Close25.00
Day's Range24.00 - 24.80
52-Week Range22.70 - 46.00
Beta0.76
RSI43.15
Earnings DateNov 19, 2025

About Poltreg

Poltreg S.A., a biotechnology company, researches and develops therapies for autoimmune diseases. It engages in the development of therapies for the treatment of type 1 diabetes in children, as well as multiple sclerosis. The company was incorporated in 2016 and is based in Gdansk, Poland. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 33
Stock Exchange Warsaw Stock Exchange
Ticker Symbol PTG
Full Company Profile

Financial Performance

In 2024, Poltreg's revenue was 350,000, a decrease of -74.98% compared to the previous year's 1.40 million. Losses were -18.71 million, 38.1% more than in 2023.

Financial Statements

News

There is no news available yet.